Demyelinating disease drug pipelines

Abbvie

Zoinbryta

Multiple sclerosis

Approved


Abbvie

ABT-555

Multiple sclerosis

Phase I


Acorda

rHlgM22

Multiple sclerosis

Phase I


Teva

Copaxone

Multiple sclerosis

Approval


Teva

Laquinimod

Multiple sclerosis (progressive), Huntington's disease & Multiple sclerosis (relapsing-remitting)

Phase II & III


Takeda

glatiramer acetate

Multiple sclerosis

Immunomodulator

Approved


Sanofi

GZ402668

Multiple sclerosis

anti-CD52 mAb

Phase I


Novartis

ofatumumab

Multiple sclerosis (relapsing)

Anti­CD­20 monoclonal antibody

Phase II


Novartis

siponimod

Multiple sclerosis (secondary progressive)

Phase III


Novartis

fingolimod

Multiple sclerosis (pediatric)

Sphingosine-1-phosphate receptor modulator

Phase III


GlaxoSmithKline

ofatumumab

neuromyelitis optica

CD20 human monoclonal antibody (s.c.)

Phase II